You have a compound for the treatment of NASH. Now what? (Pt. 1 of 3)
This is part 1 of a 3-part series. You can find part 2 here and part 3 here. Series Overview One primary barrier to getting
This is part 1 of a 3-part series. You can find part 2 here and part 3 here. Series Overview One primary barrier to getting
NASH (Nonalcoholic steatohepatitis) is increasingly common but alarmingly under-diagnosed. In this infographic, we present a snapshot of prevalence and awareness among the patient population. NASH
I have attended dozens of conferences focused on the clinical trial industry. A few months ago, our VP of Media, Kevin Hartbarger, suggested I consider
Easing the burden on clinical trial sites should be a priority for any Site Engagement team involved in patient recruitment. Developing procedures and establishing services
In recruiting and retaining patients for clinical trials, caregivers are occasionally mentioned but rarely prioritized. We know, however, that caregivers provide a wide range of
We collect so much information—there are data points everywhere, all filed into neat reports that you can color code or export to Excel or drop
Seemingly straightforward, the block-stacking game Jenga®️ is one that requires coordination, precision, and strategy. Finding the right block to move becomes increasingly difficult as the
Pharma avoids risks. Industry plays it safe. Uncertainty is discouraged, even dangerous. Sound familiar? The clinical side of pharma is more black and white than
“Feasibility” has become an umbrella term, applied to site selection criteria as well as protocol development and even patient-experience analysis—but it shouldn’t be. A “feasibility”
Managing large-scale projects as a program—comprised of a group of related projects—helps us achieve efficiencies and other benefits not available from managing the projects individually.